STVN
HealthcareStevanato Group S.p.A. · Medical - Instruments & Supplies · $5B
What is Stevanato Group S.p.A.?
Stevanato Group is an Italian-headquartered company that provides integrated solutions for the pharmaceutical and healthcare industries, spanning containment, drug delivery, and inspection equipment. It serves drug manufacturers globally from its base in Piombino Dese, Italy.
Stevanato Group designs and manufactures glass and polymer containment systems, drug delivery devices, and diagnostic components for pharma clients. It also produces visual inspection machines, assembling equipment, and packaging machinery — making it one of the few players offering both primary packaging and the engineering systems used to fill and inspect those packages.
The company was founded in 1949 and listed publicly in 2021, with headquarters in Piombino Dese, Italy.
- Glass and polymer drug containment solutions
- Drug delivery systems and medical devices
- Visual inspection and packaging machines
- Analytical and diagnostic services
Is STVN a Good Stock to Buy?
UQS Score rates STVN as Below Average overall.
The Risk pillar stands out as the relative bright spot, suggesting the business carries a manageable financial risk profile compared to many mid-cap peers. Valuation is rated Neutral, meaning the stock is neither clearly cheap nor obviously stretched by UQS criteria.
Both the Quality and Moat pillars are rated Weak, pointing to below-average returns and limited competitive differentiation — areas that warrant careful scrutiny from long-term investors.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does STVN pay dividends?
Yes — Stevanato Group S.p.A. pays a dividend.
Stevanato Group pays a regular dividend, which is relatively uncommon among mid-cap healthcare equipment companies still investing in capacity expansion. The dividend signals a degree of financial confidence from management, though investors should weigh it alongside the company's ongoing capital requirements for growth initiatives.
When does STVN report earnings?
Stevanato Group reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue trends have reflected the broader pharma packaging cycle, with demand for biologics containment remaining a key driver. Growth has been Neutral by UQS criteria, suggesting the company is expanding but not at a pace that distinguishes it from sector peers.
For the most recent quarter's results and guidance, visit Stevanato Group's investor relations page directly.
STVN Price History
-23.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Stevanato Group S.p.A.?
Based on Stevanato Group S.p.A.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
STVN Long-term Outlook
The fundamental outlook for STVN is shaped by a Neutral Growth profile and a Good Risk rating. This combination suggests the business is unlikely to deliver outsized near-term expansion, but is not facing acute financial stress. The Weak Moat rating remains a structural concern — without stronger competitive differentiation, sustaining above-average margins over time may prove difficult.
Growth drivers
- Rising demand for biologics and injectable drug packaging
- Expansion of integrated engineering and inspection systems
- Long-term pharma outsourcing trends favoring specialized suppliers
Key risks
- Weak moat leaves pricing power vulnerable to competition
- Capital-intensive manufacturing limits free cash flow flexibility
- Pharma customer concentration and order-cycle volatility
STVN vs Peers
Stevanato Group operates in a competitive segment of healthcare supply, facing rivals across medical devices, lab supplies, and pharma services.
Merit Medical focuses on single-use medical devices for interventional procedures, giving it a different end-market exposure than Stevanato's pharma packaging focus.
ICU Medical specializes in infusion therapy and critical care devices, competing more on the drug delivery side rather than primary containment.
Avantor is a large-scale materials and services provider to biopharma, overlapping with Stevanato in lab and production consumables but operating at significantly greater scale.
Frequently Asked Questions
What does Stevanato Group do?
Stevanato Group designs and manufactures drug containment systems, drug delivery devices, and pharma inspection and packaging machinery. It serves pharmaceutical and biotech companies that need integrated solutions — from the glass vial that holds a drug to the machine that inspects it before shipment.
Does STVN pay dividends?
Yes, Stevanato Group pays a regular dividend. This is notable for a mid-cap healthcare equipment company still investing in manufacturing capacity. Investors should review the current dividend details on the company's investor relations page, as amounts and timing can change.
When does STVN report earnings?
Stevanato Group reports on a quarterly cadence, in line with standard practice for US-listed companies. Specific dates are not covered by our data source — check the company's investor relations page or a financial calendar for the next scheduled report.
Is STVN a good stock to buy?
UQS Score rates STVN as Below Average, driven by Weak Quality and Moat scores. The Risk pillar is rated Good, which is a relative positive. Whether STVN fits a portfolio depends on individual goals — the full pillar breakdown is available to UQS Pro members.
Is STVN overvalued?
UQS rates STVN's Valuation pillar as Neutral, meaning it does not appear clearly overpriced or deeply discounted relative to the scoring model's criteria. Investors seeking a more detailed valuation view can access the complete analysis through a UQS Pro account.
How does STVN compare to its competitors?
Among peers like Merit Medical, ICU Medical, and Avantor, Stevanato's differentiation lies in its dual focus on primary pharma packaging and the engineering systems used in filling and inspection. Its UQS profile — particularly the Weak Moat — suggests it has not yet established a dominant competitive position relative to larger sector players.
What is STVN's market cap bracket?
Stevanato Group is classified as a mid-cap company. This places it in a segment where growth potential and institutional coverage can vary widely, and where competitive pressures from both larger and smaller specialists are common.
Who founded Stevanato Group?
Stevanato Group was founded in 1949 by the Stevanato family in Italy. The company remains majority-controlled by Stevanato Holding S.R.L., preserving significant family ownership even after its public listing in 2021.
Is STVN a long-term quality investment?
As a long-term quality indicator, UQS rates STVN as Below Average. The Weak Quality and Moat scores suggest the business has not yet demonstrated the durable returns and competitive advantages typically associated with high-conviction long-term holdings. The Good Risk rating is a stabilizing factor worth noting.
What sector does STVN belong to?
Stevanato Group operates in the Healthcare sector, specifically within pharma packaging, drug delivery, and healthcare equipment. This positions it as a supplier to the broader pharmaceutical and biotech industry rather than a drug developer itself.
Unlock Full STVN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access full financial metrics and trend data behind each pillar rating
- ✓Compare STVN side-by-side with Merit Medical, ICU Medical, and Avantor
- ✓See how STVN ranks within the Healthcare sector universe
- ✓Get the complete analyst-style view available to UQS Pro members
Pro Analysis
STVN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 46.0 | 35.3 | 38.0 | 53.7 | 69.1 | 43.8 | -1.5 |
| May 7, 2026 | 47.5 | 36.4 | 38.0 | 54.7 | 69.5 | 50.1 | -0.2 |
| May 4, 2026 | 47.7 | 36.4 | 38.0 | 54.7 | 69.5 | 51.5 | 0.0 |
| May 3, 2026 | 47.7 | 36.4 | 38.0 | 54.6 | 69.5 | 51.5 | -0.2 |
| May 1, 2026 | 47.9 | 36.4 | 38.0 | 54.6 | 69.5 | 52.7 | +0.1 |
| Apr 26, 2026 | 47.8 | 36.4 | 38.0 | 54.3 | 69.5 | 52.7 | 0.0 |
| Apr 21, 2026 | 47.8 | 36.4 | 38.0 | 55.2 | 69.5 | 51.7 | +0.1 |
| Apr 19, 2026 | 47.7 | 36.4 | 38.0 | 54.7 | 69.5 | 51.7 | -0.3 |
| Apr 18, 2026 | 48.0 | 36.4 | 38.0 | 54.7 | 69.5 | 53.8 | +0.3 |
| Apr 17, 2026 | 47.7 | 36.4 | 38.0 | 54.6 | 69.5 | 52.0 | 0.0 |
STVN — Pillar Breakdown
Quality
— 35.3/100 (25%)Stevanato Group S.p.A. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 53.6/100 (20%)Stevanato Group S.p.A. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 69.1/100 (15%)Stevanato Group S.p.A. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 43.2/100 (15%)Stevanato Group S.p.A. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 38/100 (25%)Stevanato Group S.p.A. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for STVN.
Score Composition
Financial Data
More Stock Analysis
How is the STVN UQS Score Calculated?
The UQS (Unified Quality Score) for Stevanato Group S.p.A. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Stevanato Group S.p.A.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Stevanato Group S.p.A. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.